These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32044530)

  • 1. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure.
    Pasalic D; Lu Y; Betancourt-Cuellar SL; Taku N; Mesko SM; Bagley AF; Chance WW; Allen PK; Tang C; Antonoff MB; Balter PA; Mehran RJ; Welsh JW; Liao Z; Gomez D; Erasmus JJ; Nguyen QN
    Radiother Oncol; 2020 Apr; 145():178-185. PubMed ID: 32044530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
    Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy.
    Binkley MS; Trakul N; Jacobs LR; von Eyben R; Le QT; Maxim PG; Loo BW; Shultz DB; Diehn M
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1044-1052. PubMed ID: 26025776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer.
    Pasalic D; Betancourt-Cuellar SL; Taku N; Ludmir EB; Lu Y; Allen PK; Tang C; Antonoff MB; Fuller CD; Rosenthal DI; Morrison WH; Phan J; Garden AS; Welsh JW; Chang JY; Liao Z; Erasmus JJ; Nguyen QN
    Head Neck; 2020 Aug; 42(8):1939-1953. PubMed ID: 32129548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.
    Chance WW; Nguyen QN; Mehran R; Welsh JW; Gomez DR; Balter P; Komaki R; Liao Z; Chang JY
    Pract Radiat Oncol; 2017; 7(3):e195-e203. PubMed ID: 27743801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience.
    Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S
    Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy for sarcoma pulmonary metastases.
    Lebow ES; Lobaugh SM; Zhang Z; Dickson MA; Rosenbaum E; D'Angelo SP; Nacev BA; Shepherd AF; Shaverdian N; Wolden S; Wu AJ; Gelblum DY; Simone CB; Gomez DR; Alektiar K; Tap WD; Rimner A
    Radiother Oncol; 2023 Oct; 187():109824. PubMed ID: 37532104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
    Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
    JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
    Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
    Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study.
    Debbi K; Loganadane G; To NH; Kinj R; Husain ZA; Chapet S; Nguyen NP; Barillot I; Benezery K; Belkacemi Y; Calais G
    Br J Radiol; 2022 May; 95(1133):20210033. PubMed ID: 35143326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
    Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
    Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
    Moding EJ; Liang R; Lartey FM; Maxim PG; Sung A; Diehn M; Loo BW; Gensheimer MF
    Clin Lung Cancer; 2019 Nov; 20(6):461-468.e2. PubMed ID: 31377143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
    Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.